Breast cancer risk varies among different progestins used in hormone replacement therapy

Aug 10, 2010

Progestins are used in hormone replacement therapies to counteract the negative effects of estrogen on the uterus and reduce the risk of uterine cancer. However, evidence in recent studies and clinical trials has demonstrated that progestins increase the risk of breast cancer. Now, University of Missouri researchers have compared four types of progestins used in hormone replacement therapies and found significantly different outcomes on the progression of breast cancer in an animal model depending on the type of progestins used.

"Synthetic progestins have different biological effects, due to differences in their structure, stability and how they interact in the body," said Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "Clinical use of progestins requires caution. These powerful steroids should only be prescribed when a person has no latent, or dormant, cancer and does not have a family history of cancer. However, it is difficult to diagnose latent in women since there are no symptoms."

In the study, researchers compared the effects of four clinically relevant progestins on tumors in an animal model. The progestins used in the study were the synthetic progestin medroxporgresterone acetate (MPA), norgesterel (N-EL), norethindrone (N-ONE) and megestrol acetate (MGA). In the United States, most women on are treated with MPA, the progestin in Prempro, Hyder said.

"Although previous studies using an animal model for breast cancer found that MPA functions as a tumor promoter, this study show that N-EL and N-One, when administrated using the same protocol as used for MPA, strongly inhibited tumor development," Hyder said. "Thus progestins seem to have tumor-stage specific effects, which determine whether these will function as tumor promoters or tumor suppressors. Progestins, such as N-EL and N-ONE, may have potential as preventive agents in women with no history of breast disease or family history of breast cancer. These progestins may also have a preventive role in post-menopausal women who are at an increased risk for developing breast cancer due to ingestion of combined estrogen/progestin (MPA) therapy and may have early stage disease."

The chart below shows the tumor latency and tumor incidence for the four types of progestins. Tumor latency is the period from when the animal model is first exposed to tumor cells to the first signs of cancer.

Explore further: Informed consent: False positives not a worry in lung cancer study

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Incomplete HPV vaccination may offer some protection

13 hours ago

Minority women who received the Human Papillomavirus Vaccination (HPV) even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated. These findings appear in the journal ...

New imaging agent provides better picture of the gut

13 hours ago

A multi-institutional team of researchers has developed a new nanoscale agent for imaging the gastrointestinal (GI) tract. This safe, noninvasive method for assessing the function and properties of the GI tract in real time ...

User comments : 0